(Q54704357)

3 June 2018

title

Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. (English)

1 reference

3 June 2018

1 reference

Thomas Hammerschmidt

1

1 reference

3 June 2018

Helmtrud Bisanz

series ordinal

2

1 reference

3 June 2018

Peter Wutzler

series ordinal

3

1 reference

3 June 2018

language of work or name

English

0 references

publication date

30 August 2007

1 reference

3 June 2018

published in

Vaccine

1 reference

3 June 2018

volume

25

1 reference

3 June 2018

issue

42

1 reference

3 June 2018

page(s)

7307-7312

1 reference

3 June 2018

Seroprevalence of varicella-zoster virus in the German population

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Empirical data on the varicella situation in Germany for vaccination decisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

The cost-effectiveness of routine childhood varicella vaccination in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

The economic value of childhood varicella vaccination in France and Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Decline in mortality due to varicella after implementation of varicella vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Varicella disease after introduction of varicella vaccine in the United States, 1995-2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Validation of health economic models: the example of EVITA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Efficacy of high-titer live attenuated varicella vaccine in healthy young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Control of varicella: why is a two-dose schedule necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

The hidden costs of infant vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

The use of combination vaccines has improved timeliness of vaccination in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Immunisation status of children in Germany: temporal trends and regional differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Economic evaluations of varicella vaccination programmes: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Varicella vaccination in England and Wales: cost-utility analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

The cost-effectiveness of varicella vaccination in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

Effects of varicella vaccination on herpes zoster incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.017

10.1016/J.VACCINE.2007.08.017

7 January 2021

Identifiers

DOI

1 reference

3 June 2018

release_m3ml5kgf7nfabo2emzlw2qq6ju

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m3ml5kgf7nfabo2emzlw2qq6ju

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

3 June 2018